Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gamgertamig - KeyMed Biosciences

Next Previous
Drug Profile

Gamgertamig - KeyMed Biosciences

Alternative Names: CM-336; OM-336

Latest Information Update: 27 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyMed Biosciences
  • Developer KeyMed Biosciences; Lakefront Biotherapeutics; Ouro Medicines
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia; Pemphigus; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyloidosis; Multiple myeloma
  • Phase I/II Bullous pemphigoid; Cytopenia; Haemolytic anaemia; Idiopathic thrombocytopenic purpura
  • Phase I Myositis; Pemphigus; Sjogren's syndrome
  • Clinical Phase Unknown Autoimmune haemolytic anaemia

Most Recent Events

  • 25 Aug 2026 Gamgertamig - KeyMed Biosciences receives Orphan Drug status for Pemphigus in USA
  • 20 Aug 2026 KeyMed plans a phase III trial for Multiple Myeloma (Second-line therapy or greater, Combination therapy) in August 2026
  • 10 Aug 2026 Lakefront Biotherapeutics plans proof-of-concept basket trials in Autoimmune disorders

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top